XKRX
185750
Market cap646mUSD
Oct 08, Last price
65,900.00KRW
1D
-0.45%
1Q
-6.13%
Jan 2017
-30.47%
IPO
-9.60%
Name
Chong Kun Dang Pharmaceutical Corp
Chart & performance
P/E
11.16
P/S
0.51
EPS
5,906.67
Div yield, %
0.76%
Shrs. gr., 5y
1.02%
Rev. gr., 5y
5.37%
Revenues
1.69t
+6.68%
Net income
77.83b
-28.65%
CFO
67.36b
+4.77%
Dividend
Dec 29, 2025500 KRW/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Chong Kun Dang Pharmaceutical Corp. engages in the manufacture, distribution, research, and development of pharmaceuticals. Its products include medicine for antidiabetics, antiviruses, beta-blockers, anti-hyperlipidemia, and others. The company was founded on May 7, 1941 and is headquartered in Seoul, South Korea.
Key people
Jang Han Lee
Chairman
Chun Gyeong Oh
Chief Technology Officer, Vice President
Jang Won Choi
Managing Director
Yun Han Lee
Managing Director
Managing Director, Director
Ja Min Gu
Other, Director · since 2021
Hong Bae Kim
Internal Auditor
Gi Won Kim
Director · since 2017
Yeong Ju Kim
President, Director
Seong Gon Kim
Managing Director, Director
Sun Wuk Hong
Non-Executive Independent Director
Yin Su Kang
Non-Executive Independent Director
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||